Mylan
-
{
- All
- News
- Videos
-
Biocon In Talks With Mylan To Merge Biosimilar Businesses: Report
Biocon will seek to hold a controlling majority stake in the merged entity and the companies will also look for an initial public offering (IPO).
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
Natco's Partner Mylan Inc Files ANDA for Generic Copaxone
Drug firm Natco Pharma today said its marketing partner in America, Mylan Inc has filed an ANDA for generic Copaxone used in treatment of multiple sclerosis and expects 180 days of marketing exclusivity.
-
UK says Mylan Recalls Batches of Indian-Made Antibiotic
The Medicines and Healthcare products Regulatory Agency, or MHRA, said the decision was due to the potential for small particles of white material to be present in individual vials.
-
Wockhardt denies media report on asset sale talks
Generic drugmaker Wockhardt Ltd denied on Tuesday a media report that said U.S. drugmakers Mylan Inc and Pfizer Inc were in talks with the company to buy some of its assets.
-
Pharma Sector I Complex Injectables In U.S. Market - Patent Expired, Near-Term Opportunities: Nirmal Bang
Pharma Sector I Complex Injectables In U.S. Market - Patent Expired, Near-Term Opportunities: Nirmal Bang
-
Biocon In Talks With Mylan To Merge Biosimilar Businesses: Report
Biocon will seek to hold a controlling majority stake in the merged entity and the companies will also look for an initial public offering (IPO).
-
US Body Warns Pharma Firm Mylan Over Quality In Telangana Plant: Report
Mylan NV received a warning from US regulators for failing to ensure key drug ingredients made at one of its plants in India were not contaminated.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Mylan Labs Gets Nod To Manufacture Remdesivir For COVID-19 Patients
The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for ''restricted emergency use'' on hospitalised COVID-19 patients, a senior government official said on Thursday.
-
Biocon, Mylan Launch Fulphila, Biosimilar Pegfilgrastim In Australia
The approval of Fulphila was based on a comprehensive package of analytical, nonclinical and clinical data
-
Culture of ‘Bending Rules’ in India Challenges U.S. Drug Agency
The FDA confronts creative improvisation in the world’s largest generic-drug exporter.
-
Dr. Reddy’s Bid To Revive Growth In Its Largest Market At Risk
U.S. government shutdown may hit Dr. Reddy’s plans to enter its largest market for generics of Suboxone.
-
Biocon Says Won’t Play The Bloodbath Game In Indian Market For Now
“I don’t want to play a bloodbath game in the Indian market, for now,” says Biocon’s Kiran Mazumdar-Shaw.
-
India's Lupin Starts Strategic Review of Japanese Arm
Japanese subsidiaries of Lupin produce treatments in therapeutic areas including psychiatry and neurology.
-
Biocon In Talks With Mylan To Merge Biosimilar Businesses: Report
Biocon will seek to hold a controlling majority stake in the merged entity and the companies will also look for an initial public offering (IPO).
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
Natco's Partner Mylan Inc Files ANDA for Generic Copaxone
Drug firm Natco Pharma today said its marketing partner in America, Mylan Inc has filed an ANDA for generic Copaxone used in treatment of multiple sclerosis and expects 180 days of marketing exclusivity.
-
UK says Mylan Recalls Batches of Indian-Made Antibiotic
The Medicines and Healthcare products Regulatory Agency, or MHRA, said the decision was due to the potential for small particles of white material to be present in individual vials.
-
Wockhardt denies media report on asset sale talks
Generic drugmaker Wockhardt Ltd denied on Tuesday a media report that said U.S. drugmakers Mylan Inc and Pfizer Inc were in talks with the company to buy some of its assets.
-
Pharma Sector I Complex Injectables In U.S. Market - Patent Expired, Near-Term Opportunities: Nirmal Bang
Pharma Sector I Complex Injectables In U.S. Market - Patent Expired, Near-Term Opportunities: Nirmal Bang
-
Biocon In Talks With Mylan To Merge Biosimilar Businesses: Report
Biocon will seek to hold a controlling majority stake in the merged entity and the companies will also look for an initial public offering (IPO).
-
US Body Warns Pharma Firm Mylan Over Quality In Telangana Plant: Report
Mylan NV received a warning from US regulators for failing to ensure key drug ingredients made at one of its plants in India were not contaminated.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Mylan Labs Gets Nod To Manufacture Remdesivir For COVID-19 Patients
The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for ''restricted emergency use'' on hospitalised COVID-19 patients, a senior government official said on Thursday.
-
Biocon, Mylan Launch Fulphila, Biosimilar Pegfilgrastim In Australia
The approval of Fulphila was based on a comprehensive package of analytical, nonclinical and clinical data
-
Culture of ‘Bending Rules’ in India Challenges U.S. Drug Agency
The FDA confronts creative improvisation in the world’s largest generic-drug exporter.
-
Dr. Reddy’s Bid To Revive Growth In Its Largest Market At Risk
U.S. government shutdown may hit Dr. Reddy’s plans to enter its largest market for generics of Suboxone.
-
Biocon Says Won’t Play The Bloodbath Game In Indian Market For Now
“I don’t want to play a bloodbath game in the Indian market, for now,” says Biocon’s Kiran Mazumdar-Shaw.
-
India's Lupin Starts Strategic Review of Japanese Arm
Japanese subsidiaries of Lupin produce treatments in therapeutic areas including psychiatry and neurology.
